List of Tables
Table 1. Neoantigen Cancer Vaccine Market Trends
Table 2. Neoantigen Cancer Vaccine Market Drivers & Opportunity
Table 3. Neoantigen Cancer Vaccine Market Challenges
Table 4. Neoantigen Cancer Vaccine Market Restraints
Table 5. Global Neoantigen Cancer Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Neoantigen Cancer Vaccine Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Neoantigen Cancer Vaccine Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Neoantigen Cancer Vaccine Product Type
Table 9. Key Companies Time to Begin Mass Production of Neoantigen Cancer Vaccine
Table 10. Global Neoantigen Cancer Vaccine Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Cancer Vaccine as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Neoantigen Cancer Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Neoantigen Cancer Vaccine Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Neoantigen Cancer Vaccine Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Neoantigen Cancer Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Neoantigen Cancer Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Neoantigen Cancer Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Neoantigen Cancer Vaccine Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Neoantigen Cancer Vaccine Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Neoantigen Cancer Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Neoantigen Cancer Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Neoantigen Cancer Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Neoantigen Cancer Vaccine Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Neoantigen Cancer Vaccine Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Neoantigen Cancer Vaccine Sales Value by Region (2019-2024) & (%)
Table 27. Global Neoantigen Cancer Vaccine Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Neoantigen Cancer Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Neoantigen Cancer Vaccine Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Neoantigen Cancer Vaccine Sales Value, (2025-2030) & (US$ Million)
Table 31. Roche Basic Information List
Table 32. Roche Description and Business Overview
Table 33. Roche Neoantigen Cancer Vaccine Products, Services and Solutions
Table 34. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Roche (2019-2024)
Table 35. Roche Recent Developments
Table 36. Medimmune Basic Information List
Table 37. Medimmune Description and Business Overview
Table 38. Medimmune Neoantigen Cancer Vaccine Products, Services and Solutions
Table 39. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Medimmune (2019-2024)
Table 40. Medimmune Recent Developments
Table 41. Merck Basic Information List
Table 42. Merck Description and Business Overview
Table 43. Merck Neoantigen Cancer Vaccine Products, Services and Solutions
Table 44. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Merck (2019-2024)
Table 45. Merck Recent Developments
Table 46. Advaxis Basic Information List
Table 47. Advaxis Description and Business Overview
Table 48. Advaxis Neoantigen Cancer Vaccine Products, Services and Solutions
Table 49. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Advaxis (2019-2024)
Table 50. Advaxis Recent Developments
Table 51. Agenus Basic Information List
Table 52. Agenus Description and Business Overview
Table 53. Agenus Neoantigen Cancer Vaccine Products, Services and Solutions
Table 54. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Agenus (2019-2024)
Table 55. Agenus Recent Developments
Table 56. Genocea Basic Information List
Table 57. Genocea Description and Business Overview
Table 58. Genocea Neoantigen Cancer Vaccine Products, Services and Solutions
Table 59. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Genocea (2019-2024)
Table 60. Genocea Recent Developments
Table 61. Gritstone Oncology Basic Information List
Table 62. Gritstone Oncology Description and Business Overview
Table 63. Gritstone Oncology Neoantigen Cancer Vaccine Products, Services and Solutions
Table 64. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Gritstone Oncology (2019-2024)
Table 65. Gritstone Oncology Recent Developments
Table 66. Neon Therapeutics Basic Information List
Table 67. Neon Therapeutics Description and Business Overview
Table 68. Neon Therapeutics Neoantigen Cancer Vaccine Products, Services and Solutions
Table 69. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Neon Therapeutics (2019-2024)
Table 70. Neon Therapeutics Recent Developments
Table 71. Nouscom Basic Information List
Table 72. Nouscom Description and Business Overview
Table 73. Nouscom Neoantigen Cancer Vaccine Products, Services and Solutions
Table 74. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Nouscom (2019-2024)
Table 75. Nouscom Recent Developments
Table 76. OSE Immunotherapeutics Basic Information List
Table 77. OSE Immunotherapeutics Description and Business Overview
Table 78. OSE Immunotherapeutics Neoantigen Cancer Vaccine Products, Services and Solutions
Table 79. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of OSE Immunotherapeutics (2019-2024)
Table 80. OSE Immunotherapeutics Recent Developments
Table 81. Medigene Basic Information List
Table 82. Medigene Description and Business Overview
Table 83. Medigene Neoantigen Cancer Vaccine Products, Services and Solutions
Table 84. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Medigene (2019-2024)
Table 85. Medigene Recent Developments
Table 86. Vaccibody Basic Information List
Table 87. Vaccibody Description and Business Overview
Table 88. Vaccibody Neoantigen Cancer Vaccine Products, Services and Solutions
Table 89. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Vaccibody (2019-2024)
Table 90. Vaccibody Recent Developments
Table 91. Brightpath Biotherapeutics Basic Information List
Table 92. Brightpath Biotherapeutics Description and Business Overview
Table 93. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Products, Services and Solutions
Table 94. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Brightpath Biotherapeutics (2019-2024)
Table 95. Brightpath Biotherapeutics Recent Developments
Table 96. Geneos Therapeutics Basic Information List
Table 97. Geneos Therapeutics Description and Business Overview
Table 98. Geneos Therapeutics Neoantigen Cancer Vaccine Products, Services and Solutions
Table 99. Revenue (US$ Million) in Neoantigen Cancer Vaccine Business of Geneos Therapeutics (2019-2024)
Table 100. Geneos Therapeutics Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. Neoantigen Cancer Vaccine Downstream Customers
Table 104. Neoantigen Cancer Vaccine Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Neoantigen Cancer Vaccine Product Picture
Figure 2. Global Neoantigen Cancer Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Neoantigen Cancer Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 4. Neoantigen Cancer Vaccine Report Years Considered
Figure 5. Global Neoantigen Cancer Vaccine Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Neoantigen Cancer Vaccine Revenue in 2023
Figure 7. Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Personalized Vaccine Picture
Figure 9. Off-the-shelf Neovaccines Picture
Figure 10. Global Neoantigen Cancer Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Neoantigen Cancer Vaccine Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Hospital
Figure 13. Product Picture of Clinic
Figure 14. Product Picture of Others
Figure 15. Global Neoantigen Cancer Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Neoantigen Cancer Vaccine Sales Value Market Share by Application, 2023 & 2030
Figure 17. North America Neoantigen Cancer Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 18. North America Neoantigen Cancer Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 19. Europe Neoantigen Cancer Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 20. Europe Neoantigen Cancer Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 21. Asia Pacific Neoantigen Cancer Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 22. Asia Pacific Neoantigen Cancer Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 23. South America Neoantigen Cancer Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 24. South America Neoantigen Cancer Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 25. Middle East & Africa Neoantigen Cancer Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 26. Middle East & Africa Neoantigen Cancer Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 27. Key Countries/Regions Neoantigen Cancer Vaccine Sales Value (%), (2019-2030)
Figure 28. United States Neoantigen Cancer Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 29. United States Neoantigen Cancer Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 30. United States Neoantigen Cancer Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 31. Europe Neoantigen Cancer Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 32. Europe Neoantigen Cancer Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 33. Europe Neoantigen Cancer Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 34. China Neoantigen Cancer Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 35. China Neoantigen Cancer Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 36. China Neoantigen Cancer Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 37. Japan Neoantigen Cancer Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 38. Japan Neoantigen Cancer Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 39. Japan Neoantigen Cancer Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 40. South Korea Neoantigen Cancer Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 41. South Korea Neoantigen Cancer Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 42. South Korea Neoantigen Cancer Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 43. Southeast Asia Neoantigen Cancer Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Neoantigen Cancer Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 45. Southeast Asia Neoantigen Cancer Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 46. India Neoantigen Cancer Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 47. India Neoantigen Cancer Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 48. India Neoantigen Cancer Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 49. Neoantigen Cancer Vaccine Industrial Chain
Figure 50. Neoantigen Cancer Vaccine Manufacturing Cost Structure
Figure 51. Channels of Distribution (Direct Sales, and Distribution)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
